{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9","value":"173"},{"groupId":"OG001","spread":"14","value":"376"}]}],"title":"Cycle 1 Day 1 (n=3,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"237"},{"groupId":"OG001","spread":"18","value":"549"}]}],"title":"Cycle 1 Day 8 (n=3,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10","value":"297"},{"groupId":"OG001","spread":"21","value":"652"}]}],"title":"Cycle 1 Day 15 (n=3,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14","value":"234"},{"groupId":"OG001","spread":"45","value":"724"}]}],"title":"Cycle 1 Day 22 (n=3,2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"240"},{"groupId":"OG001","spread":"51","value":"671"}]}],"title":"Cycle 2 Day 1 (n=3,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"270"},{"groupId":"OG001","spread":"26","value":"844"}]}],"title":"Cycle 2 Day 22 (n=3,3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32","value":"286"},{"groupId":"OG001","spread":"32","value":"972"}]}],"title":"Cycle 3 Day 1 (n=3,3)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"The quantification of elotuzumab in human serum was performed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (µg/mL). Samples of serum were obtained at: Cycle 1, Day 1: 0 hour (h), 30 minutes (min) 2 h post dose; Day 8: 0h, 2 h; Day 15: 0h, 30 min; Day 22: 0h, 30min, 2h. Cycle 2, Day 1, 22 0h, 2h. Cycle 3, Day 1: 0h, 30h, 2h; Day 15: 0h.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Elotuzumab was administered IV at a dose of 10 mg/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).","id":"OG000","title":"Elotuzumab 10 mg/kg"},{"description":"Elotuzumab was administered IV at a dose of 20 mg/kg weekly (Days 1, 8, 15 and 22 of 4-week cycle) for the first 2 cycles and bi-weekly (every 2 weeks) (Day 1 and Day 15) thereafter until disease progression or unacceptable toxicity became apparent. Lenalidomide 25 mg was administered PO once daily for the first 3 weeks of each 4-week cycle. The dose of lenalidomide was administered at least 2-4 hours after completion of elotuzumab infusion. On weeks without elotuzumab administration, dexamethasone was administered PO as a single dose of 40 mg. On weeks of elotuzumab infusion, the weekly dose of dexamethasone was administered as a split dose of: 28 mg PO (between 3 to 24 hours prior to the start of the elotuzumab infusion) and 8 mg IV (At least 45 min prior to the start of the elotuzumab infusion).","id":"OG001","title":"Elotuzumab 20 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study medication and had adequate Pharmacokinetic (PK) concentration profiles were summarized.","reportingStatus":"POSTED","timeFrame":"Days 1, 8, 15 and 22 of cycle 1, Days 1 and 22 of cycle 2, Days 1 and 15 of cycle 3","title":"Geometric Mean Maximum Observed Serum Elotuzumab Concentration (Cmax) During Cycles 1, 2, and 3","type":"SECONDARY","unitOfMeasure":"µg/mL"}